[ Alzheimer’s Drug Discovery Foundation – Prevention pipeline | Research Funding ]
Event details
| Date | 28.05.2021 |
| Category | Call for proposal |
Aim: The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Specifically, the Prevention Pipeline RFP supports:
Current target areas of interest include:
Funding: max. $3M (clinical trials)
Duration: Multi-year
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits.
How to Apply: Deadlines for proposal submissions occur three times per year. Applications are reviewed in a two-step process: Letters of Intent (LOIs) are the first step. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Winter Deadlines: 05-February-2021 (LOI)
16-April-2021 (full proposal, by invitation)
Summer Deadlines: 28-May-2021 (LOI)
30-July-2021 (full proposal, by invitation)
Autumn Deadlines: 01-October-2021 (LOI)
03-December-2021 (full proposal, by invitation)
Further information
Specifically, the Prevention Pipeline RFP supports:
- Studies of Cognitive Decline and Risk Reduction
- Comparative Effectiveness Research
- Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA)
Current target areas of interest include:
- Epigenetics
- Inflammation
- Mitochondria & metabolic function
- Neuroprotection
- Proteostasis
- Synaptic activity and neurotransmitters
- Vascular function
- Other aging target (e.g. senescent cells)
- Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process
Funding: max. $3M (clinical trials)
Duration: Multi-year
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits.
How to Apply: Deadlines for proposal submissions occur three times per year. Applications are reviewed in a two-step process: Letters of Intent (LOIs) are the first step. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Winter Deadlines: 05-February-2021 (LOI)
16-April-2021 (full proposal, by invitation)
Summer Deadlines: 28-May-2021 (LOI)
30-July-2021 (full proposal, by invitation)
Autumn Deadlines: 01-October-2021 (LOI)
03-December-2021 (full proposal, by invitation)
Further information
- More information about the program is available here
- Detailed application instructions are here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free